5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Biopharmaceuticals Market is segmented by products (monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, synthetic immunomodulators, and vaccines), by application, and by geography
Fastest growing market:
Market Size in 2024:
$ 389 Billion
The global biopharmaceuticals market was valued at USD 237,250.8 million in 2018, and is estimated to be valued at USD 388,997.3 million in 2024, witnessing a CAGR of 8.59%. The market growth is attributed to the growing acceptance for biopharmaceuticals due to their ability to treat previously untreatable diseases, resulting in huge market demand for biopharmaceuticals.
Biopharmaceuticals offer several benefits, such as highly effective and potent action, fewer side effects, and the potential to actually cure diseases rather than merely treat the symptoms, which have significantly increased the demand for biopharmaceutical products.
Biopharmaceuticals have reduced the number of deaths due to cancer and HIV/AIDS in the past decade, which has led to an increase in the adoption of biopharmaceuticals in the global market.
Biopharmaceuticals have given an alternative to the previously less effective and sometimes unsafe treatments, and it allows clinicians to tailor treatments to the specific medical problems experienced by each patient.
For the scope of the report, the term biopharmaceutical refers to any biologically synthesized molecule that is used to treat or manage disorders.
|By Product Type|
|By Therapeutic Application|
|Inflammatory and Infectious Diseases|
Report scope can be customized per your requirements. Click here.
Among the given segments, monoclonal antibodies are believed to have the largest market size. This can be attributed to the growing research done with the help of monoclonal antibodies. On the other hand, the recombinant enzymes segment is expected to show rapid growth during the forecast period.
Monoclonal antibodies (mAbs) find their application in the areas of cancer treatment. Their use is becoming prevalent in developed countries, such as the United States and the United Kingdom. The mAb drugs in oncology are gaining momentum and growing at a decent pace. The segment is dominating the market currently, and the trend is expected to be followed in the future.
The recombinant enzymes, such as Enterokinase, are gaining attraction because of their efficacy in the digestion of the dietary proteins. Over the years, 100% native protein sequences have been produced using Enterokinase. This application has improved the market scope for this particular enzyme in the recent years.
To understand key trends, Download Sample Report
North America currently dominates the market for biopharmaceuticals, and is expected to continue its stronghold for a few more years. Asia-Pacific is expected to increase its market share in the future owing to increase in the prevalence of diseases, such as diabetes and cancer, along with the regulatory framework that is feasible for the approval of biopharmaceuticals in the region. The United States holds the majority of the market in the North American region; this is due to the increasing prevalence of chronic diseases. In addition, there is a rise in per capita health expenditure in the country that is expected to increase over the forecast period, owing to the decrease in the unemployment rate.
To understand geography trends, Download Sample Report.
The biopharmaceuticals market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products with less prices. Companies, like Amgen Inc., Eli Lily & Company, Johnson & Johnson, and Pfizer Inc. hold a significant share in the biopharmaceuticals market.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Acceptance for Biopharmaceuticals
4.2.2 Ability of Biopharmaceuticals to Treat Previously Untreatable Diseases
4.2.3 Huge Market Demand
4.3 Market Restraints
4.3.1 Increasing Demand for Affordable Biopharmaceuticals
4.3.2 High-end Manufacturing Requirements
4.3.3 Complicated and Cumbersome Regulatory Requirements
5. MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Monoclonal Antibodies
188.8.131.52 Anti Cancer Monoclonal Antibodies
184.108.40.206 Anti-inflammatory Monoclonal Antibodies
220.127.116.11 Other Monoclonal Antibodies
5.1.2 Recombinant Growth Factors
18.104.22.168 Granulocyte Colony Stimulating Factor
5.1.3 Purified Proteins
22.214.171.124 Leukemia Inhibitory Factor (LIF)
126.96.36.199 P53 Protein
188.8.131.52 P38 Protein
184.108.40.206 Other Purified Proteins
5.1.4 Recombinant Proteins
220.127.116.11 Serum Albumin
18.104.22.168 Amyloid Protein
5.1.5 Recombinant Hormones
22.214.171.124 Recombinant Hormones
126.96.36.199 Recombinant Insulin
188.8.131.52 Other Recombinant Hormones
184.108.40.206 Recombinant Vaccines
220.127.116.11.1 Cancer Vaccines
18.104.22.168.2 Malaria Vaccines
22.214.171.124.3 Ebola Vaccine
126.96.36.199.4 Hepatitis-b Vaccine
188.8.131.52.5 Tetanus Vaccine
184.108.40.206.6 Diptheria Vaccine
220.127.116.11.7 Cholera Vaccine
18.104.22.168.8 Other Vaccines
22.214.171.124 Conventional Vaccines
126.96.36.199.1 Polio Vaccine
188.8.131.52.2 Pox Vaccine
184.108.40.206.3 Other Conventional Vaccines
220.127.116.11 Recombinant Enzymes
18.104.22.168 Cell and Gene Therapies
22.214.171.124.1 Allogeneic Products
126.96.36.199.2 Autologous Products
188.8.131.52.3 Acellular Products
184.108.40.206 Other Product Types
220.127.116.11.1 Blood Factors
18.104.22.168.2 Other Product Types
5.1.7 Synthetic Immunomodulators
22.214.171.124 Cytokines, Interferones, Interleukins
126.96.36.199 Tumor Necrosis Factor (TNF)
5.2 By Therapeutic Application
5.2.2 Inflammatory and Infectious Diseases
5.2.3 Autoimmune Disorders
5.2.4 Metabolic Disorders
5.2.5 Hormonal Disorders
5.2.6 Disease Prevention
5.2.7 Cardiovascular Diseases
5.2.8 Neurological Diseases
5.2.9 Other Diseases
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
5.3.3 Asia Pacific
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East & Africa
5.3.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbvie Inc.
6.1.2 Amgen Inc.
6.1.3 Bristol-Myers Squibb Company
6.1.4 Eli Lily & Co.
6.1.5 Johnson & Johnson
6.1.6 Novartis AG
6.1.7 Novo Nordisk Inc.
6.1.8 Pfizer Inc.
6.1.9 GlaxoSmithKline PLC
6.1.10 Roche Holding AG
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments